Page 246 - Binder2

Commercialization: From Clinics to Kitchens?

On the commercial side, edible biologics challenge many
assumptions:

• Where are they dispensed? Pharmacy? Mail
order? Clinical setting?
• How are they priced? As biologics? Supplements?
Chronic care therapies?
• Who pays for them? Insurers? Governments?
NGOs? Patients?
• How are they perceived? Natural? Experimental?
Disruptive? Scalable?

The answers will depend on the use case—but there are real
advantages:

• No infusion costs
• Reduced cold chain requirements
• Simplified patient experience
• Higher potential for adherence
• Lower manufacturing overhead

If priced and positioned wisely, edible biologics could
undercut traditional biologics by orders of magnitude—
especially in global markets where access is limited and
infrastructure is thin.

Strategically, developers should consider:

• Early partnerships with payers interested in long-
term cost reduction
• Collaborations with health ministries or NGOs for
global pilot programs
• Exploration of pharmacy benefit models for oral
biologics

244